Гиперурикемия и сердечно-сосудистые заболевания


DOI: https://dx.doi.org/10.18565/therapy.2020.7.71-82

С.В. Тополянская

ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)
Гиперурикемия издавна считается основным этиологическим фактором подагры, однако в последние годы установлено, что она может играть роль и в патогенезе ряда сердечно-сосудистых и метаболических заболеваний. Даже бессимптомная гиперурикемия оказывает существенное негативное воздействие на сердечно-сосудистую систему и приводит к атеросклерозу, ишемической болезни сердца, хронической сердечной недостаточности, фибрилляции предсердий, артериальной гипертензии и острому нарушению мозгового кровообращения. При этом существуют значимые взаимосвязи между уровнем мочевой кислоты в крови и многими факторами риска сердечно-сосудистых заболеваний (инсулинорезистентностью, метаболическим синдромом, ожирением, неалкогольной жировой болезнью печени и хронической болезнью почек). Точные механизмы взаимосвязи между мочевой кислотой и сердечно-сосудистой патологией пока не установлены, однако в недавних исследованиях показана ключевая роль системного воспаления, индуцированного гиперурикемией. В целом накопленные к настоящему времени данные свидетельствуют о важной роли гиперурикемии при различных сердечно-сосудистых заболеваниях.
Ключевые слова: мочевая кислота, гиперурикемия, атеросклероз, ишемическая болезнь сердца, хроническая сердечная недостаточность, фибрилляция предсердий, артериальная гипертензия
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Di Stolfo G., Mastroianno S., Potenza D.R. et al. Serum uric acid as a prognostic marker in the setting of advanced vascular disease: A prospective study in the elderly. J Geriatr Cardiol. 2015; 12(5): 515–20. doi: 10.11909/j.issn.1671-5411.2015.05.008.

  2. Gustafsson D., Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14(1): 164. doi: 10.1186/1471-2369-14-164.

  3. Biscaglia S. Ceconi C., Malagu M. et al. Uric acid and coronary artery disease: An elusive link deserving further attention. Int J Cardiol. 2016; 213: 28–32. doi: 10.1016/j.ijcard.2015.08.086.

  4. Puddu P., Puddu G.M., Cravero E. et al. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol. 2012; 59(3): 235–42. doi: 10.1016/j.jjcc.2012.01.013.

  5. Strasak A., Ruttmann E., Brant L. et al. Serum uric acid and risk of cardiovascular mortality: A prospective long-term study of 83 683 Austrian men. Clin Chem Narnia. 2008; 54(2): 273–84. doi: 10.1373/clinchem.2007.094425.

  6. Ndrepepa G. Uric acid and cardiovascular disease. Clinica Chimica Acta. 2018; 484:150–63. doi: 10.1016/j.cca.2018.05.046.

  7. Battelli M.G., Bolognesi A., Polito L. Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme. Biochim Biophys Acta. 2014; 1842(9): 1502–17. doi: 10.1016/j.bbadis.2014.05.022.

  8. Marotta T., Liccardo M., Schettini F. et al. Association of hyperuricemia with conventional cardiovascular risk factors in elderly patients. J. Clin. Hypertens. 2015; 17 (1): 27–32. doi: 10.1111/jch.12434.

  9. Kanbay M., Segal M., Afsar B. et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013; 99(11): 759–66. doi: 10.1136/heartjnl-2012-302535.

  10. So A., Thorens B. Uric acid transport and disease. J Clin Invest. 2010; 120(6): 1791–99. doi: 10.1172/JCI42344.

  11. Kim Y.S., Guevara J.P., Mi Kim K. et al. Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010; 62(2): 170–80. doi: 10.1002/acr.20065.

  12. McMullan C.J., Borgi L., Fisher N. et al. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: A randomized controlled trial. Clin J Am Soc Nephrol. 2017; 12(5): 807–16. doi: 10.2215/CJN.10771016.

  13. Cheng T.-H., Lin J.-W., Chao H.-H. et al. Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol. 2010; 139(1): 42–49. doi: 10.1016/j.ijcard.2008.09.004.

  14. Cicerchi C., Li N., Kratzer J. et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J. 2014; 28(8): 3339–50. doi: 10.1096/fj.13-243634.

  15. Lyngdoh T., Marques-Vidal P., Paccaud F. et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One. 2011; 6(5): e19901. doi: 10.1371/journal.pone.0019901.

  16. Tanaka T., Milaneschi Y., Zhang Y. et al. A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: A pilot study. PLoS One. 2017; 12(8): 8–9. doi: 10.1371/journal.pone.0181100.

  17. Prasad M., Matteson E.L., Herrmann J. et al. Uric acid is associated with inflammation, coronary microvascular dysfunction, and adverse outcomes in postmenopausal women. Hypertension. 2017; 69(2): 236–42. doi: 10.1161/HYPERTENSIONAHA.116.08436.

  18. Zhu Y., Pandya B., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Exanination Survey 2007–2008. Arthritis Rheum. 2011; 63(10): 3136–41. doi: 10.1002/art.30520.

  19. Trivedi N. Uric acid and cardiovascular risk. New England Journal of Medicine. N Engl J Med. 2009; 360(5): 539; author reply 540-1.

  20. Johnson R.J., Sautin Y.Y., Oliver W.J. et al. Lessons from comparative physiology: Could uric acid represent a physiologic alarm signal gone awry in western society? J Comp Physiol B. 2009; 179(1):67–76. doi: 10.1007/s00360-008-0291-7.

  21. Li M., Hu X., Fan Y. et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 2016; 6: 19520. doi: 10.1038/srep19520.

  22. Fang J., Alderman M.H. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA. 2000; 283(18): 2404–10. doi: 10.1001/jama.283.18.2404.

  23. Holme I., Aastveit A.H., Hamma N. et al. Uric Acid and Risk of Myocardial Infarction, Stroke and Congestive Heart Failure in 417,734 Men and Women in the Apolipoprotein MOrtality RISk Study (AMORIS). J Intern Med. 2009; 266(6): 558–70. doi: 10.1111/j.1365-2796.2009.02133.x.

  24. Bos M.J., Koudstaal P.J., Hofman A. et al. Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam Study. Stroke. 2006; 37(6): 1503–07. doi: 10.1161/01.STR.0000221716.55088.d4.

  25. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham heart study. Ann Intern Med. 1999; 131(1): 7–13. doi: 10.7326/0003-4819-131-1-199907060-00003.

  26. Wheeler J.G., Juzwishin K.D.M., Eiriksdottir G. et al. Serum Uric Acid and Coronary Heart Disease in 9,458 Incident Cases and 155,084 Controls: Prospective Study and Meta-Analysis. PLoS Med. 2005; 2(3): e76. doi: 10.1371/journal.pmed.0020076.

  27. Zalawadiya S.K., Veeranna V., Mallikethi-Reddy S. et al. Uric acid and cardiovascular disease risk reclassification: findings from NHANES III. Eur J Prev Cardiol. 2015; 22(4): 513–18. doi: 10.1177/2047487313519346.

  28. Chen J.-H., Chuang S.-Y., Chen H.-J. et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: A Chinese cohort study. Arthritis Rheum. 2009; 61(2): 225–32. doi: 10.1002/art.24164.

  29. Chuang S.Y., Chen J.-H., Yeh W.-T. et al. Hyperuricemia and increased risk of ischemic heart disease in a large Chinese cohort. Int J Cardiol. 2012; 154(3): 316–21. doi: 10.1016/j.ijcard.2011.06.055.

  30. Strasak A.M., Kelleher C.C., Brant L.J. et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: A prospective 21-year follow-up study. Int J Cardiol. 2008; 125(2): 232–39. doi: 10.1016/j.ijcard.2007.11.094.

  31. Storhaug H.M., Norvik J.V., Toft I. et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromso Study. BMC Cardiovasc. Disord. 2013; 13(1): 115. doi: 10.1186/1471-2261-13-115.

  32. Tseng W.C., Chen Y.-T., Ou S.-M. et al. U-shaped association between serum uric acid levels with cardiovascular and all-cause mortality in the elderly: The role of malnourishment. J Am Heart Assoc. 2018; 7(4): 2018–19. doi: 10.1161/JAHA.117.007523.

  33. Feng L., Hua C., Sun H. et al. Association between serum uric acid level and carotid atherosclerosis in Chinese individuals aged 75 years or older: a hospital-based case-control study. J Nutrition Health Aging. 2018; 22: 508–12. doi: 10.1007/s12603-017-0984-2.

  34. Neogi T., Ellison R.C., Hunt S. et al. Serum uric acid is associated with carotid plaques: The National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol. 2009; 36(2): 378–84. doi: 10.3899/jrheum.080646.

  35. Tavil Y., Kaya M.G., Oktar S.O. et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis. 2008; 197(1): 159–63. doi: 10.1016/j.atherosclerosis.2007.03.008.

  36. Kim H., Kim S.-H., Choi A.R. et al. Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease. Medicine (Baltimore). 2017; 96(14): e6565. doi: 10.1097/MD.0000000000006565.

  37. Calvo R.Y., Araneta M.R.G., Kritz-Silverstein D. et al. Relation of serum uric acid to severity and progression of coronary artery calcium in postmenopausal white and Filipino women (from the Rancho Bernardo study). Am J Cardiol. 2014; 113(7): 1153–58. doi: 10.1016/j.amjcard.2013.12.022.

  38. Zhao G., Huang L., Song M., Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: A meta-analysis of prospective studies. Atherosclerosis. 2013; 231(1): 61–68. doi: 10.1016/j.atherosclerosis.2013.08.023.

  39. Braga F., Pasqualetti S., Ferraro S., Panteghini M. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: A systematic review and meta-analysis. Clin Chem Lab Med. 2016; 54(1): 7–15. doi: 10.1515/cclm-2015-0523.

  40. Zhong C., Zhong X., Xu T. et al. Sex-specific relationship between serum uric acid and risk of stroke: a dose-response meta-analysis of prospective studies. J Am Heart Assoc. 2017; 6(4): e005042. doi: 10.1161/JAHA.116.005042.

  41. Keenan T., Zhao W., Rasheed A. et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016; 67(4): 407–16. doi: 10.1016/j.jacc.2015.10.086.

  42. Li X., Meng X., Timofeeva M. et al. Serum uric acid levels and multiple health outcomes: Umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. BMJ. 2017; 357: j2376. doi: 10.1136/bmj.j2376.

  43. Ndrepepa G., Braun S., King L. et al. Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism. 2012; 61(12): 1780–86. doi: 10.1016/j.metabol.2012.05.014.

  44. Ndrepepa G., Cassese S., Braun S. et al. A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. Nutr Metab Cardiovasc Dis. 2013; 23(12): 1195–201. doi: 10.1016/j.numecd.2013.03.005.

  45. Okura T., Higaki J., Kurata M. et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J. 2009; 73(5): 885–91. doi: 10.1253/circj.cj-08-0828.

  46. Spoon D.B., Lerman A., Rule A.D. et al. The Association of serum uric acid levels with outcomes following percutaneous coronary intervention. J Interv Cardiol. 2010; 23(3): 277–83. doi: 10.1111/j.1540-8183.2010.00555.x.

  47. Silbernagel G., Hoffmann M.M., Grammer T.B. et al. Uric acid is predictive of cardiovascular mortality and sudden cardiac death in subjects referred for coronary angiography. Nutr. Metab. Cardiovasc. Dis. 2013; 23 (1): 46–52. doi: 10.1016/j.numecd.2011.02.008.

  48. Ndrepepa G., Braun S., King L. et al. Uric acid and prognosis in angiography-proven coronary artery disease. Eur J Clin Invest. 2013; 43(3): 256–66. doi: 10.1111/eci.12039.

  49. Wang R., Song Y., Yan Y., Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis. 2016; 254: 193–99. doi: 10.1016/j.atherosclerosis.2016.10.006.

  50. Xu Q., Zhang M., Abeysekera I.R., Wang X. High serum uric acid levels may increase mortality and major adverse events in ptients with acute myocardial infarction. Saudi Med. J. 2017; 38(6): 577–85. doi: 10.15537/smj.2017.6.17190.

  51. Lazzeri C., Valente S., Chiostri M. et al. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: Its prognostic role and relation with inflammatory markers. A single center experience. Int J Cardiol. 2010; 138(2): 206–09. doi: 10.1016/j.ijcard.2008.06.024.

  52. Lazzeri C., Valente S., Chiostri M. et al. Uric acid in the early risk stratification of ST-elevation myocardial infarction. Intern Emerg Med. 2012; 7(1): 33–39. doi: 10.1007/s11739-011-0515-9.

  53. Krishnan E. Hyperuricemia and incident heart failure. Circ Hear Fail. 2009; 2(6): 556–62. doi: 10.1161/CIRCHEARTFAILURE.108.797662.

  54. Ekundayo O.J., Dell’Italia L.J., Sanders P.W. et al. Association between hyperuricemia and incident heart failure among older adults: A propensity-matched study. Int J Cardiol. 2010; 14(3): 279–87. doi: 10.1016/j.ijcard.2009.01.010.

  55. Wannamethee S.G., Papacosta O., Lennon L., Whincup P.H. Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study. Int J Cardiol. 2018; 252: 187–92. doi: 10.1016/j.ijcard.2017.11.083.

  56. Huang H., Huang B., Li Y. et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014; 16(1): 15–24. doi: 10.1093/eurjhf/hft132.

  57. Palazzuoli A., Ruocco G., De Vivo O. et al. Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction. Am J Cardiol. 2017; 12(7): 1146–50. doi: 10.1016/j.amjcard.2017.06.057.

  58. Krishnan E., Hariri. A., Dabbous O., Pandya B.J. Hyperuricemia and the echocardiographic measures of myocardial dysfunction. Congest Hear Fail. 2012; 18(3): 138–43. doi: 10.1111/j.1751-7133.2011.00259.x.

  59. Cicoira M., Zanolla L., Rossi A. et al. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J. 2002; 143(6): 1107–11. doi: 10.1067/mhj.2002.122122.

  60. Doehner W., Jankowska E.A., Springer J. et al. Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications. Int J Cardiol. 2016; 213: 15–19. doi: 10.1016/j.ijcard.2015.08.089.

  61. Schuchardt M., Herrmann J., Tolle M., van der Giet M. Xanthine oxidase and its role as target in cardiovascular protection by enzyme inhibition? Curr Pharm Des. 2017; 23(23): 3391–404. doi: 10.2174/1381612823666170417130115.

  62. Wu A.H., Gladden J.D., Ahmed M. et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016; 213: 4–7. doi: 10.1016/j.ijcard.2015.08.110.

  63. Tamariz L., Hernandez F., Bush A. et al. Association between serum uric acid and atrial fibrillation: A systematic review and meta-analysis. Hear. Rhythm. 2014; 11(7): 1102–08. doi: 10.1016/j.hrthm.2014.04.003.

  64. Hirsch G.A., Bottomley P.A., Gerstenblith G., Weiss R.G. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012; 59(9): 802–08. doi: 10.1016/j.jacc.2011.10.895.

  65. Cingolani H.E., Plastino J.A., Escudero E.M. et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail. 2006; 12(7): 491–98. doi: 10.1016/j.cardfail.2006.05.005.

  66. Kazuhide O., Kinugasa Y., Kato M. et al. Uric-acid lowering treatment by a xanthine oxidase inhibitor improved the diastolic function in patients with hyperuricemia. Journal of cardiac failure. 2019; 25(8): S26. doi: 10.1016/j.cardfail.2019.07.071.

  67. Hare J.M., Mangal B., Brown J. et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008; 51(24): 2301–09. doi: 10.1016/j.jacc.2008.01.068.

  68. Givertz M.M., Anstrom K.J., Redfield M.M. et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: The xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015; 131(20): 1763–71. doi: 10.1161/CIRCULATIONAHA.114.014536.

  69. Feig D.I., Kang D.-H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17): 1811–21. doi: 10.1056/NEJMra0800885.

  70. Kuwabara M., Hisatome I., Niwa K. et al. Uric acid is a strong risk marker for developing hypertension from prehypertension: A 5-year Japanese cohort study. Hypertension. 2018; 71 (1): 78–86. doi: 10.1161/HYPERTENSIONAHA.117.10370.

  71. Kuwabara M. Hyperuricemia, cardiovascular disease, and hypertension. Pulse. 2016; 3 (3–4): 242–52. doi: 10.1159/000443769.

  72. Loeffler L.F., Navas-Acien A., Brady T.M. et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. Hypertension. 2012; 59(4): 811–17. doi: 10.1161/HYPERTENSIONAHA.111.183244.

  73. Feig D.I., Soletsky B., Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA. 2008; 300(8): 924–32. doi: 10.1001/jama.300.8.924.

  74. Soletsky B., Feig D.I. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012; 60(5): 1148–56. doi: 10.1161/HYPERTENSIONAHA.112.196980.

  75. Agarwal V., Hans N., Messerli F.H. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013; 15(6): 435–42. doi: 10.1111/j.1751-7176.2012.00701.x.

  76. Gois P.H.F., de Moraes Souza E.R. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev. 2017; 4(4): CD008652. doi: 10.1002/14651858.

  77. Чазова И.Е., Жернакова Ю.В., Кисляк О.А. с соавт. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 4: 8–21.

  78. Franse L.V., Pahor M., Di Bari M. et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program (SHEP). J Hypertens. 2000 Aug; 18(8): 1149–54. doi: 10.1097/00004872-200018080-00021.

  79. Hamada T., Ichida K., Hosoyamada M. et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008; 21(10): 1157–62. doi: 10.1038/ajh.2008.245.

  80. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for themanagement of arterial hypertension. European Heart Journal. 2018; 39(33): 3021–104. doi: 10.1093/eurheartj/ehy339.

  81. Чазова И.Е., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Клинические рекомендации. Системные гипертензии. 2019; 1: 6–31.

  82. Watanabe E. Uric acid and atrial fibrillation – cause or other association? Circ J. 2012; 76(3): 584–85. doi: 10.1253/circj.cj-12-0057.

  83. Korantzopoulos P., Letsas K.P., Liu T. Xanthine oxidase and uric acid in atrial fibrillation. Front Physiol. 2012; 3: 150. doi: 10.3389/fphys.2012.00150.

  84. Chen Y., Xia Y., Han X. et al. Association between serum uric acid and atrial fibrillation: A cross-sectional community-based study in China. BMJ Open. 2017; 7(12): 1–7. doi: 10.1136/bmjopen-2017-019037.

  85. Kuwabara M., Niwa K., Hisatome I. Hyperuricemia is an independent risk factor of atrial fibrillation. J Am Coll Cardiol. 2014; 63(12): A469.

  86. Maharani N., Kuwabara M., Hisatome I. Hyperuricemia and atrial fibrillation: Possible underlying mechanisms. Int Heart J 2016; 57(4): 395–99. doi: 10.1536/ihj.16-192.

  87. Chuang S.Y., Wu C.-C., Hsu P.-F. et al. Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in Taiwan. Nutr Metab Cardiovasc Dis. 2014; 24(9): 1020–26. doi: 10.1016/j.numecd.2014.03.012.

  88. Liu Y. Hyperuricemia and risk of atrial fibrillation. J Atr Fibrillation. 2014; 6(5): 967. doi: 10.4022/jafib.967.

  89. Valbusa F., Bertolini L., Bonapace S. et al. Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. Am J Cardiol. 2013; 112(4): 499–504. doi: 10.1016/j.amjcard.2013.04.012.

  90. Kawasoe S., Kubozono T., Yoshifukuet S. al. Uric acid level and prevalence of atrial fibrillation in a Japanese general population of 285,882. Circ J. 2016; 80(12): 2453–59. doi: 10.1253/circj.CJ-16-0766.

  91. Huang G., Xu R.-H., Xu J.-B. et al. Hyperuricemia is associated with atrial fibrillation prevalence in very elderly – a community based study in Chengdu, China. Sci Rep. 2018; 8(1): 12403. doi: 10.1038/s41598-018-30321-z.

  92. Tamariz L., Agarwal S., Soliman E.Z. et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities

  93. Korantzopoulos P., Letsas K., Fragakis N. et al. Oxidative stress and atrial fibrillation: an update. Free Radical Research. 2018; 52(11–12): 1199–209. doi: 10.1080/10715762.2018.1500696.

  94. Guo Y., Lip G.Y.H., Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012; 60(22): 2263–70. doi: 10.1016/j.jacc.2012.04.063.


Об авторах / Для корреспонденции

Светлана Викторовна Тополянская, к.м.н., доцент кафедры госпитальной терапии № 2 ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет). Адрес: 127299, г. Москва, ул. Клары Цеткин, д. 9, к. 2. Тел.: 8 (916) 031-51-88. E-mail: sshekshina@yahoo.com. ORCID: http://orcid.org/0000-0002-4131-8432

К содержанию номера

Бионика Медиа